Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


suck pdf from google scholar
unlimited free pdf from europmc32770825    free
PDF from PMC    free
html from PMC    free
PDF vom PMID32770825 :   free

suck abstract from ncbi

Nephropedia Template TP Text

Twit Text FOAVip

Twit Text #

English Wikipedia

  • Bacterial co-infections with SARS-CoV-2 #MMPMID32770825
  • Mirzaei R; Goodarzi P; Asadi M; Soltani A; Aljanabi HAA; Jeda AS; Dashtbin S; Jalalifar S; Mohammadzadeh R; Teimoori A; Tari K; Salari M; Ghiasvand S; Kazemi S; Yousefimashouf R; Keyvani H; Karampoor S
  • IUBMB Life 2020[Oct]; 72 (10): 2097-2111 PMID32770825show ga
  • The pandemic coronavirus disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), has affected millions of people worldwide. To date, there are no proven effective therapies for this virus. Efforts made to develop antiviral strategies for the treatment of COVID-19 are underway. Respiratory viral infections, such as influenza, predispose patients to co-infections and these lead to increased disease severity and mortality. Numerous types of antibiotics such as azithromycin have been employed for the prevention and treatment of bacterial co-infection and secondary bacterial infections in patients with a viral respiratory infection (e.g., SARS-CoV-2). Although antibiotics do not directly affect SARS-CoV-2, viral respiratory infections often result in bacterial pneumonia. It is possible that some patients die from bacterial co-infection rather than virus itself. To date, a considerable number of bacterial strains have been resistant to various antibiotics such as azithromycin, and the overuse could render those or other antibiotics even less effective. Therefore, bacterial co-infection and secondary bacterial infection are considered critical risk factors for the severity and mortality rates of COVID-19. Also, the antibiotic-resistant as a result of overusing must be considered. In this review, we will summarize the bacterial co-infection and secondary bacterial infection in some featured respiratory viral infections, especially COVID-19.
  • |*Pandemics[MESH]
  • |Acinetobacter baumannii/drug effects/pathogenicity[MESH]
  • |Anti-Bacterial Agents/*therapeutic use[MESH]
  • |Antiviral Agents/*therapeutic use[MESH]
  • |Bacterial Infections/drug therapy/*epidemiology/microbiology/virology[MESH]
  • |COVID-19/drug therapy/*epidemiology/microbiology/virology[MESH]
  • |Coinfection[MESH]
  • |Haemophilus influenzae/drug effects/pathogenicity[MESH]
  • |Host-Pathogen Interactions/immunology[MESH]
  • |Humans[MESH]
  • |Immunity, Innate/drug effects[MESH]
  • |Klebsiella pneumoniae/drug effects/pathogenicity[MESH]
  • |Legionella pneumophila/drug effects/pathogenicity[MESH]
  • |Methicillin-Resistant Staphylococcus aureus/drug effects/pathogenicity[MESH]
  • |Pneumonia, Bacterial/drug therapy/*epidemiology/microbiology/virology[MESH]
  • |Pseudomonas aeruginosa/drug effects/pathogenicity[MESH]
  • |Respiratory System/drug effects/microbiology/pathology/virology[MESH]
  • |SARS-CoV-2/drug effects/pathogenicity[MESH]
  • |Streptococcus pneumoniae/drug effects/pathogenicity[MESH]
  • |Streptococcus pyogenes/drug effects/pathogenicity[MESH]

  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    2097 10.72 2020